Fiche publication
Date publication
décembre 2021
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier
Tous les auteurs :
Rio E, Mornex F, Maingon P, Peiffert D, Parent L
Lien Pubmed
Résumé
We present the update of the recommendations of the French society of oncological radiotherapy on hepatic tumours. Recent technological progress led to develop the concept of focused liver radiation therapy. We must distinguish primary and secondary tumours, as the indications are restricted and must be discussed as an alternative to surgical or medical treatments. The tumour volume, its liver location close to the organs at risk determine the irradiation technique (repositioning method, total dose delivered, dose fractionation regimens). Tumour (and liver) breathing related motions should be taken into account. Strict dosimetric criteria must be observed with particular attention to the dose-volume histograms of non-tumoral liver as well as of the hollow organs, particularly in case of hypofractionated high dose radiotherapy "under stereotaxic conditions". Stereotactic body radiotherapy is being evaluated and is often preferred to radiofrequency for primary or secondary tumours (usually less than 5cm). An adaptation can be proposed, with a conformal fractionated irradiation protocol with or without intensity modulation, for hepatocellular carcinomas larger than 5cm.
Mots clés
Carcinome hépatocellulaire, Foie, French society for radiation oncology, Guidelines, Hepatocellular carcinoma, Liver, Liver metastasis, Métastases hépatiques, Radiation therapy, Radiothérapie, Radiothérapie en conditions stéréotaxiques, Recommandations, Société française de radiothérapie oncologique, Stereotactic radiotherapy
Référence
Cancer Radiother. 2021 Dec 14;:
